Pacira BioSciences Inc. (PCRX)
Pacira BioSciences, Inc. Class Action: Levi & Korsinsky Reminds Pacira Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 14, 2025 - PCRX
NEW YORK, NY / ACCESSWIRE / January 14, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
PCRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Pacira BioSciences, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / January 14, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Pacira BioSciences, Inc. ("Pacira" or "the Company") (NASDAQ:PCRX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Pacira securities between August 2, 2023 and August 8, 2024, both dates inclusive (the "Class Period").
Pacira BioSciences, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your Rights – PCRX
NEW YORK, NY / ACCESSWIRE / January 13, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
PCRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Pacira BioSciences, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / January 13, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Pacira BioSciences, Inc. ("Pacira" or "the Company") (NASDAQ:PCRX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Pacira securities between August 2, 2023 and August 8, 2024, both dates inclusive (the "Class Period").
PCRX Stock Rises 11% on Upbeat Q4 Preliminary Product Sales
Pacira stock gains 11% on better-than-expected preliminary Q4 sales figures. It also shares a strategic growth plan to drive innovation and value creation by 2030.
Pacira (PCRX) Soars 11.1%: Is Further Upside Left in the Stock?
Pacira (PCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Investors who lost money on Pacira BioSciences, Inc. should contact Levi & Korsinsky about an ongoing investigation - PCRX
NEW YORK, NY / ACCESSWIRE / January 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.
Lost Money on Pacira BioSciences, Inc. (PCRX)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.
Lost Money on Pacira BioSciences, Inc. (PCRX)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / January 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.
FDA Clears PCRX's New Iovera Smart Tip for Expanded Use in Pain Relief
Pacira receives FDA approval for a new iovera Smart Tip aimed at expanding pain management capabilities to deeper nerves like the medial branch nerve.
Pacira BioSciences, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - PCRX
NEW YORK, NY / ACCESSWIRE / January 8, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.
Pacira BioSciences, Inc. Being Investigated on Behalf of Pacira BioSciences, Inc. Investors. Contact Levi & Korsinsky For Details.
NEW YORK, NY / ACCESSWIRE / January 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.
